tetano
Editor, Senior Moderator
Vaccine
. 2023 Oct 21:S0264-410X(23)01253-7.
doi: 10.1016/j.vaccine.2023.10.051. Online ahead of print. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86
Ninaad Lasrado[SUP] 1 [/SUP], Ai-Ris Y Collier[SUP] 1 [/SUP], Nicole P Hachmann[SUP] 1 [/SUP], Jessica Miller[SUP] 1 [/SUP], Marjorie Rowe[SUP] 1 [/SUP], Eleanor D Schonberg[SUP] 1 [/SUP], Stefanie L Rodrigues[SUP] 1 [/SUP], Austin LaPiana[SUP] 1 [/SUP], Robert C Patio[SUP] 1 [/SUP], Trisha Anand[SUP] 1 [/SUP], Jana Fisher[SUP] 1 [/SUP], Camille R Mazurek[SUP] 1 [/SUP], Ruoran Guan[SUP] 1 [/SUP], Kshitij Wagh[SUP] 2 [/SUP], James Theiler[SUP] 2 [/SUP], Bette T Korber[SUP] 2 [/SUP], Dan H Barouch[SUP] 3 [/SUP]
Affiliations
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb titers are substantially lower to BA.2.86 compared with BA.2 but are similar or slightly higher than to other current circulating variants, including XBB.1.5, EG.5.1, and FL.1.5.1. Moreover, NAb titers against all these variants were higher in vaccinated individuals with a history of XBB.1.5 infection compared with vaccinated individuals with no history of XBB.1.5 infection, suggesting the potential utility of the monovalent XBB.1.5 mRNA boosters.
Keywords: BA.2.86; Neutralizing antibody; SARS-CoV-2; Vaccine; mRNA.
. 2023 Oct 21:S0264-410X(23)01253-7.
doi: 10.1016/j.vaccine.2023.10.051. Online ahead of print. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86
Ninaad Lasrado[SUP] 1 [/SUP], Ai-Ris Y Collier[SUP] 1 [/SUP], Nicole P Hachmann[SUP] 1 [/SUP], Jessica Miller[SUP] 1 [/SUP], Marjorie Rowe[SUP] 1 [/SUP], Eleanor D Schonberg[SUP] 1 [/SUP], Stefanie L Rodrigues[SUP] 1 [/SUP], Austin LaPiana[SUP] 1 [/SUP], Robert C Patio[SUP] 1 [/SUP], Trisha Anand[SUP] 1 [/SUP], Jana Fisher[SUP] 1 [/SUP], Camille R Mazurek[SUP] 1 [/SUP], Ruoran Guan[SUP] 1 [/SUP], Kshitij Wagh[SUP] 2 [/SUP], James Theiler[SUP] 2 [/SUP], Bette T Korber[SUP] 2 [/SUP], Dan H Barouch[SUP] 3 [/SUP]
Affiliations
- PMID: 37872011
- DOI: 10.1016/j.vaccine.2023.10.051
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb titers are substantially lower to BA.2.86 compared with BA.2 but are similar or slightly higher than to other current circulating variants, including XBB.1.5, EG.5.1, and FL.1.5.1. Moreover, NAb titers against all these variants were higher in vaccinated individuals with a history of XBB.1.5 infection compared with vaccinated individuals with no history of XBB.1.5 infection, suggesting the potential utility of the monovalent XBB.1.5 mRNA boosters.
Keywords: BA.2.86; Neutralizing antibody; SARS-CoV-2; Vaccine; mRNA.